Verition Fund Management LLC Aerovate Therapeutics, Inc. Transaction History

Verition Fund Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$2.37 - $2.7 $92,702 - $105,610	-39,115 Reduced 41.33%	55,520 $139,000
Q4 2024 Feb 14, 2025	SELL	$1.99 - $2.79 $10,308 - $14,452	-5,180 Reduced 5.19%	94,635 $250,000
Q3 2024 Nov 14, 2024	SELL	$1.61 - $2.09 $240,110 - $311,696	-149,137 Reduced 59.91%	99,815 $208,000
Q2 2024 Aug 14, 2024	BUY	$1.41 - $30.75 $351,022 - $7.66 Million	248,952 New	248,952 $413,000

1.63M

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $65.5M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.